Fagron N.V.

Capital/Financing Update • Apr 1, 2016

Regulated information Waregem (Belgium)/Rotterdam (The Netherlands)¹, 1 April 2016

Fagron obtains extension of waiver from financiers

Fagron is pleased to announce that it has been granted an extension of the existing waiver in respect of the financial covenants on the revolving credit facility and the US private placement. This waiver was previously provided until the end of March 2016 and has now been extended to the end of June 2016 to reflect the timeline required to complete the proposed capital increase.

The extension of the waiver till the end of June 2016 means that during this period, Fagron will not be required to fulfil the financial covenants applying to the loans. This will allow Fagron to concentrate on reaching agreement on an amendment of the Company's existing financing arrangements and the proposed capital increase for a total amount of € 220 million to safeguard its financial situation for the longer term

Financial calendar 2016

12 April	Trading update, first quarter 2016
14 April	Extraordinary General Meeting of Shareholders (link to convocation and agenda)
$4$ May *	Second Extraordinary General Meeting of Shareholders
9 May	General Meeting of Shareholders
5 August	Half-year figures 2016
12 October	Trading update, third quarter 2016

* The second Extraordinary General Meeting of Shareholders will take place if the quorum required by law to validly deliberate and vote is not reached at the Extraordinary General Meeting of Shareholders of 14 April.

In the event of differences between the English translation and the Dutch original of this press release, the latter prevails.

For more information:

Constantijn van Rietschoten Chief Marketing Officer Tel. +31 6 53 69 15 85 constantijn.van.rietschoten@fagron.com

Fagron profile

Fagron is a scientific pharmaceutical R&D business focused on optimising and innovating personalised pharmaceutical care. Fagron provides Fagron Specialty Pharma Services, Fagron Trademarks and Fagron Essentials to pharmacies, clinics and hospitals in 32 countries worldwide.

The Belgian company Fagron NV is located in Waregem and is listed on Euronext Brussels and Euronext Amsterdam. The operational activities of Fagron are driven by the Dutch company Fagron BV. The head office of Fagron BV is located in Rotterdam.